Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2012 /
Shortening the timeline for clinical drug developments

28th - 29th Jun 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.07.12
Views: 5388
Rating:

Dr James Doroshow – National Cancer Institute, Bethesda, USA

Dr James Doroshow talks to ecancer at the 2012 WIN Symposium, Paris, about improving the assessment of developing targeted therapies to determine their future efficacy and the continuing sub division of cancer types.

 

Using biopsies and imaging techniques, preliminary evidence in only a few dozen patients can help researchers to understand the course of a drug's development.

 

Dr Doroshow also discusses the future of precision medicine and personalised medicine, in so far as the development of drugs and clinical trials is more about catering to the patient rather than the drug's future.

 

Dr Doroshow predicts all cancers becoming ‘rare’ types as each tumour and mutation is identified in each patient. This intense classification of disease type highlights the importance of creating national and global databases. 

 

Filming Supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation